MS
NAMS icon

Maven Securities’s NewAmsterdam Pharma NAMS Stock Holding History

Maven Securities’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-150,000
Closed -$3.85M – 924
2024
Q4 		$3.85M Buy
+150,000
New +$3.19M 0.09% 172
2023
Q4 		– Sell
-25,000
Closed -$231K – 1123
2023
Q3 		$231K Hold
25,000
– – ﹤0.01% 1011
2023
Q2 		$297K Buy
+25,000
New +$332K ﹤0.01% 733

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Maven Securities's NAMS Position: Q1 2025 in Review

Maven Securities sold out of NewAmsterdam Pharma (NAMS) in Q1 2025, closing a stake of 150,000 shares — an estimated $3.85M sold.

Maven Securities first reported a position in NAMS in Q2 2023 and held it in 3 quarters. The position peaked at $3.85M in Q4 2024. 126 funds tracked by Wall St. Rank hold NAMS as of Q1 2025.

  • Maven Securities reported no remaining NewAmsterdam Pharma position as of Q1 2025 after selling out during the quarter.
  • Maven Securities sold 150,000 NewAmsterdam Pharma shares in Q1 2025, an estimated $3.85M.
  • Maven Securities first reported a position in NewAmsterdam Pharma in Q2 2023 and held it in 3 quarters.
  • Maven Securities's NewAmsterdam Pharma position peaked at $3.85M in Q4 2024.
  • 126 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2025.

Based on Maven Securities's 13F filing for Q1 2025, filed 14 May 2025.